MNTA—Necuparanib (M402) PR on phase-1 portion of phase-1/2 trial in pancreatic cancer: http://ir.momentapharma.com/releasedetail.cfm?ReleaseID=875538 Reminder: MNTA is holding an R&D Day webcast tomorrow from 8:30am-Noon ET.